Literature DB >> 36248814

Enlarged perivascular spaces, neuroinflammation and neurological dysfunction in NMOSD patients.

Xiao-Ying Yao1, Mei-Chun Gao1, Shu-Wei Bai1, Li Xie2, Ya-Ying Song1, Jie Ding1, Yi-Fan Wu1, Chun-Ran Xue1, Yong Hao1, Ying Zhang1, Yang-Tai Guan1.   

Abstract

Background and objectives: Cerebrospinal fluid (CSF) and interstitial fluid exchange along a brain-wide network of perivascular spaces (PVS) termed the 'glymphatic system'. The aquaporin-4 (AQP4) water channels abundantly expressed on astrocytic endfeet play a key role in the CSF circulation in the glymphatic system. Neuromyelitis optica spectrum disorder (NMOSD) is an inflammatory demyelinating autoimmune disease of the central nervous system (CNS) featured with a specific autoantibody directed against AQP4 in most of patients. Anti-AQP4 antibodies are likely resulting in the impairment of the brain glymphatic system and the enlargement of PVS in NMOSD patients. In the current study, we aimed to demonstrate the features of EPVS detected by MRI and its association with the CSF anti-AQP4 antibody titer, CNS inflammatory markers, and disease severity in NMOSD patients.
Methods: We conducted a retrospective review of a consecutive cohort of 110 patients with NMOSD who had brain MRI. We assessed the correlation of EPVS with markers of neuroinflammation, blood-brain barrier (BBB) function and severity of neurological dysfunction in patients. We used multivariate logistic regression analysis to determine the independent variables associated with disease severity.
Results: The median number of total-EPVS was 15.5 (IQR, 11-24.2) in NMOSD patients. The number of total-EPVS was significantly related to EDSS score after correcting for the effects of age and hypertension (r=0.353, p<0.001). The number of total-EPVS was also significantly associated with the titer of CSF anti-AQP4 antibody, the albumin rate (CSF/serum ratios of albumin), the CSF albumin, IgG and IgA levels. Logistic regression analysis showed that total-EPVS and serum albumin level were two independent factors to predict disease severity in NMOSD patients (OR=1.053, p=0.028; OR=0.858, p=0.009 respectively). Furthermore, ROC analysis achieved AUC of 0.736 (0.640-0.831, p<0.001) for total-EPVS to determine severe NMOSD (EDSS 4.5-9.5). Discussion: In our cohort, we found a relationship between EPVS and neuroinflammation and BBB function in NMOSD. Moreover, EPVS might independently predict neurological dysfunction in patients with NMOSD.
Copyright © 2022 Yao, Gao, Bai, Xie, Song, Ding, Wu, Xue, Hao, Zhang and Guan.

Entities:  

Keywords:  blood brain barrier (BBB); glymphatic circulation; neuroinflammation; neuromyelitis optica spectrum disorders (not in MeSH); perivascular spaces

Mesh:

Substances:

Year:  2022        PMID: 36248814      PMCID: PMC9557144          DOI: 10.3389/fimmu.2022.966781

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   8.786


  35 in total

1.  Sandlike appearance of Virchow-Robin spaces in early multiple sclerosis: a novel neuroradiologic marker.

Authors:  Anat Achiron; Meir Faibel
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

Review 2.  The role of brain barriers in fluid movement in the CNS: is there a 'glymphatic' system?

Authors:  N Joan Abbott; Michelle E Pizzo; Jane E Preston; Damir Janigro; Robert G Thorne
Journal:  Acta Neuropathol       Date:  2018-02-10       Impact factor: 17.088

3.  Inflammation and cerebral small vessel disease: A systematic review.

Authors:  Audrey Low; Elijah Mak; James B Rowe; Hugh S Markus; John T O'Brien
Journal:  Ageing Res Rev       Date:  2019-06-10       Impact factor: 10.895

4.  Revised diagnostic criteria for neuromyelitis optica.

Authors:  D M Wingerchuk; V A Lennon; S J Pittock; C F Lucchinetti; B G Weinshenker
Journal:  Neurology       Date:  2006-05-23       Impact factor: 9.910

Review 5.  Perivascular spaces, glymphatic dysfunction, and small vessel disease.

Authors:  Humberto Mestre; Serhii Kostrikov; Rupal I Mehta; Maiken Nedergaard
Journal:  Clin Sci (Lond)       Date:  2017-08-10       Impact factor: 6.124

6.  Anatomical relationships of the pia mater to cerebral blood vessels in man.

Authors:  M Hutchings; R O Weller
Journal:  J Neurosurg       Date:  1986-09       Impact factor: 5.115

7.  Enlarged perivascular spaces and small diffusion-weighted lesions in intracerebral hemorrhage.

Authors:  Bo Wu; Xiaoying Yao; Chunyan Lei; Ming Liu; Magdy H Selim
Journal:  Neurology       Date:  2015-11-06       Impact factor: 9.910

8.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration.

Authors:  Joanna M Wardlaw; Eric E Smith; Geert J Biessels; Charlotte Cordonnier; Franz Fazekas; Richard Frayne; Richard I Lindley; John T O'Brien; Frederik Barkhof; Oscar R Benavente; Sandra E Black; Carol Brayne; Monique Breteler; Hugues Chabriat; Charles Decarli; Frank-Erik de Leeuw; Fergus Doubal; Marco Duering; Nick C Fox; Steven Greenberg; Vladimir Hachinski; Ingo Kilimann; Vincent Mok; Robert van Oostenbrugge; Leonardo Pantoni; Oliver Speck; Blossom C M Stephan; Stefan Teipel; Anand Viswanathan; David Werring; Christopher Chen; Colin Smith; Mark van Buchem; Bo Norrving; Philip B Gorelick; Martin Dichgans
Journal:  Lancet Neurol       Date:  2013-08       Impact factor: 44.182

9.  Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder.

Authors:  Remi A Kessler; Maureen A Mealy; Michael Levy
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-07-28

Review 10.  Perivascular spaces in the brain: anatomy, physiology and pathology.

Authors:  Joanna M Wardlaw; Helene Benveniste; Maiken Nedergaard; Berislav V Zlokovic; Humberto Mestre; Hedok Lee; Fergus N Doubal; Rosalind Brown; Joel Ramirez; Bradley J MacIntosh; Allen Tannenbaum; Lucia Ballerini; Ravi L Rungta; Davide Boido; Melanie Sweeney; Axel Montagne; Serge Charpak; Anne Joutel; Kenneth J Smith; Sandra E Black
Journal:  Nat Rev Neurol       Date:  2020-02-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.